News | June 09, 2014

Toshiba Re-enters U.S. Nuclear Imaging Market With New PET/CT System

June 9, 2014 — Toshiba America Medical Systems Inc. announced the release of its Celesteion system for positron emission tomography/computed tomography (PET/CT) imaging. The Celesteion is currently pending 510(k) clearance from the U.S. Food and Drug Administration (FDA).

The system combines high-performance PET and CT for all radiation and oncology imaging needs, including tumor detection, treatment evaluation and CT simulation. Features include:

  • A 90 cm CT and 88 cm PET bore, offering a feeling of openness for patients and more accurate CT and PET imaging;
  • Fast imaging for reduced exam times;
  • 450 ps time-of-flight resolution for PET;
  • 0.5-second rotation with 0.5 mm detectors producing 32 slices for CT;
  • 70 cm true CT and PET field-of-view and 85 cm CT extended field-of-view; and
  • Toshiba’s CT dose reduction technology, AIDR 3D, for safer CT imaging. The system is also compliant with MITA’s XR-29 Smart Dose standard.

“By listening to our customers and understanding their business, we know there is a need for a PET/CT system that puts patients first, and the Celesteion is that solution,” said Satrajit Misra, senior director, CT Business Unit, Toshiba. “Accuracy and efficiency are crucial under healthcare reform, and Celesteion is capable of producing high-quality images while improving workflow for providers.”

The Celesteion was first unveiled at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. It is Toshiba’s first nuclear imaging system for the American market in seven years and is an effort to capture larger a share of the SPECT (single-photon emission computed tomography) system replacement and first-generation PET/CT replacement market.

For more information: www.medical.toshiba.com

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init